SEC Tracker
Get the app

Recursion Pharmaceuticals RXRX

Fred Hassan (Director) received 156,658 RXRX

Form
4
Filed
Importance
Routine
  1. 156,658 Class A Common Stock acquired
  2. Restricted stock units (shares paid out over time) granted on Nov 2, 2026
  3. Vesting over three years starting Nov 2, 2026

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Recursion Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Bausch Health Companies BHC public float $2.0B, Jun 30, 2025
  2. Vericel VCEL public float $2.1B, Jun 30, 2025
  3. Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
  4. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  5. Indivior Pharmaceuticals INDV public float $1.8B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.